Kiniksa Pharmaceuticals International, plc — Revenue by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/668df63d-7a00-493c-a449-d64ecc5f91a2/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $677.6M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-019168 |
| FY 2024 | $423.2M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-001505 |
| FY 2023 | $270.3M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002005 |
| FY 2022 | $220.2M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002684 |
| FY 2021 | $38.5M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-001932 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Kiniksa Pharmaceuticals International, plc — all facts · Net Income · Operating Income